Lexicon Pharmaceuticals (LXRX) Cost of Revenue (2017 - 2026)
Lexicon Pharmaceuticals' (LXRX) quarterly Cost of Revenue came in at $108000.0 in Q1 2026, up 260.0% year-on-year from $30000.0 in Q1 2025, and down 46.27% on a QoQ basis from $201000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Cost of Revenue (2017 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 8 years of Cost of Revenue data on file, last reported at $108000.0 in Q1 2026.
- On a quarterly basis, Cost of Revenue rose 260.0% year-over-year to $108000.0 in Q1 2026; TTM through Mar 2026 was $352000.0, a 42.76% decrease from a year earlier, with the FY2025 full-year figure at $274000.0, down 55.52% from the prior year.
- Cost of Revenue for Q1 2026 stood at $108000.0, down from $201000.0 in the prior quarter.
- Over the last five years, Cost of Revenue for LXRX reached as high as $348000.0 in Q4 2024 and fell as low as $7000.0 in Q3 2023.
- Historically, Cost of Revenue has averaged $90250.0 across 4 years, with a median of $51500.0 in 2023.
- Across the five-year window, Cost of Revenue surged 1975.0% in 2024 and plunged 85.92% in 2025, its largest moves.
- Year by year, Cost of Revenue stood at $70000.0 in 2023, then surged by 397.14% to $348000.0 in 2024, then slumped by 42.24% to $201000.0 in 2025, then slumped by 46.27% to $108000.0 in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $108000.0 in Q1 2026, $201000.0 in Q4 2025, and $10000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 121.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 922.55 Mn | 751.90 Mn | 20.99 Mn | 108,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 108,000.00 |
| Mar 31, 2026 | 108,000.00 |
| Dec 31, 2025 | 201,000.00 |
| Dec 31, 2025 | 201,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 166,000.00 |
| Jun 30, 2024 | 166,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |